[{"id":"472eb807-ca9c-41c2-9b36-97f85b9dac47","acronym":"","url":"https://clinicaltrials.gov/study/NCT06754267","created_at":"2025-02-26T07:54:58.245Z","updated_at":"2025-02-26T07:54:58.245Z","phase":"Phase 2","brief_title":"Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL","source_id_and_acronym":"NCT06754267","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-12-31"},{"id":"e6e36ef9-1a28-4271-9c2d-5395fb082dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT06390306","created_at":"2024-04-30T19:56:36.690Z","updated_at":"2024-07-02T16:35:06.686Z","phase":"","brief_title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","source_id_and_acronym":"NCT06390306","lead_sponsor":"Peking University People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • Nailike (olverembatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"a1883b53-73f3-453e-8ef7-b1371ebdbfa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06051409","created_at":"2023-09-22T14:11:00.722Z","updated_at":"2024-07-02T16:35:07.843Z","phase":"Phase 3","brief_title":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.","source_id_and_acronym":"NCT06051409","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2024-04-24"},{"id":"57d72b12-2ee4-465b-8e35-96a6d9527fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03594422","created_at":"2021-01-18T17:40:27.278Z","updated_at":"2024-07-02T16:35:14.185Z","phase":"Phase 1","brief_title":"A Study of HQP1351 in Patients With GIST or Other Solid Tumors","source_id_and_acronym":"NCT03594422","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" NF1 • SDHB","pipe":" | ","alterations":" NF1 mutation","tags":["NF1 • SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-03-19"},{"id":"dac5d115-7904-464c-a96a-a31864a53af9","acronym":"ABC","url":"https://clinicaltrials.gov/study/NCT06220487","created_at":"2024-01-24T16:19:51.060Z","updated_at":"2024-07-02T16:35:22.410Z","phase":"Phase 2","brief_title":"A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL","source_id_and_acronym":"NCT06220487 - ABC","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • prednisone • Epidaza (chidamide) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-01-24"},{"id":"e0e532d7-0ae4-4b3b-bdf9-5d695ffa6ad2","acronym":"HQP1351CU101","url":"https://clinicaltrials.gov/study/NCT04260022","created_at":"2021-01-18T20:42:08.490Z","updated_at":"2024-07-02T16:35:27.872Z","phase":"Phase 1","brief_title":"Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL","source_id_and_acronym":"NCT04260022 - HQP1351CU101","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/09/2020","start_date":" 01/09/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2023-11-28"},{"id":"0f30e8cc-e8ba-41fd-a2e7-b2c56db4229b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05594784","created_at":"2022-10-26T13:56:22.126Z","updated_at":"2024-07-02T16:35:34.673Z","phase":"Phase 2","brief_title":"Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL","source_id_and_acronym":"NCT05594784","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • vincristine • prednisone • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/08/2022","start_date":" 10/08/2022","primary_txt":" Primary completion: 10/25/2024","primary_completion_date":" 10/25/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-10-05"},{"id":"c109ebf6-b9b1-4934-ad4e-d7453551a3a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05931757","created_at":"2023-07-05T14:08:41.454Z","updated_at":"2024-07-02T16:35:43.958Z","phase":"Phase 2","brief_title":"A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL","source_id_and_acronym":"NCT05931757","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Nailike (olverembatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2023-07-04"},{"id":"efb2f664-87fd-4928-b92b-66faede8e3da","acronym":"HQP1351CC203","url":"https://clinicaltrials.gov/study/NCT04126681","created_at":"2021-01-18T20:09:35.310Z","updated_at":"2024-07-02T16:35:51.472Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT04126681 - HQP1351CC203","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Nailike (olverembatinib) • Synribo (omacetaxine mepesuccinate) • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-04-04"},{"id":"50226b99-8358-4ad0-8621-32e95b1c54e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03883087","created_at":"2021-01-17T17:19:06.579Z","updated_at":"2024-07-02T16:35:51.584Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation","source_id_and_acronym":"NCT03883087","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-04-03"},{"id":"877c2407-059c-400b-92f0-7a18fad4757c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03883100","created_at":"2021-01-17T17:19:06.908Z","updated_at":"2024-07-02T16:35:51.626Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation","source_id_and_acronym":"NCT03883100","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-04-03"},{"id":"c9859f5d-e371-4f88-a60c-1b70ab251051","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495035","created_at":"2022-08-10T12:55:24.639Z","updated_at":"2024-07-02T16:35:54.315Z","phase":"Phase 1","brief_title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","source_id_and_acronym":"NCT05495035","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • Nailike (olverembatinib) • lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-02"},{"id":"f41c435f-7131-43cc-872e-3b243a791504","acronym":"Case-Only","url":"https://clinicaltrials.gov/study/NCT05376852","created_at":"2022-05-17T12:54:20.119Z","updated_at":"2024-07-02T16:35:59.375Z","phase":"Phase 2","brief_title":"Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML","source_id_and_acronym":"NCT05376852 - Case-Only","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • decitabine • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-08"},{"id":"09c5114e-3284-4aac-8196-a7093db33b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05603156","created_at":"2022-11-02T14:56:54.979Z","updated_at":"2024-07-02T16:36:01.193Z","phase":"","brief_title":"A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive","source_id_and_acronym":"NCT05603156","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 expression","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin) • Nailike (olverembatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2022-11-02"},{"id":"5b7049ab-53c4-4c94-b0b7-c26f3333e0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05466175","created_at":"2022-07-20T13:55:18.923Z","updated_at":"2024-07-02T16:36:04.600Z","phase":"Phase 2","brief_title":"A Study of Olverembatinib in the Treatment of Ph+ ALL","source_id_and_acronym":"NCT05466175","lead_sponsor":"Chen Suning","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Nailike (olverembatinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2022-09-01"},{"id":"fda6b348-a56b-40aa-9321-d8dc4bbbe723","acronym":"","url":"https://clinicaltrials.gov/study/NCT05521204","created_at":"2022-08-30T20:55:57.190Z","updated_at":"2024-07-02T16:36:04.755Z","phase":"Phase 2","brief_title":"Olverembatinib for FGFR1-rearranged Neoplasms","source_id_and_acronym":"NCT05521204","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2022-08-30"},{"id":"24f3bc30-033f-4a2f-b4f2-33d165ce15a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05311943","created_at":"2022-04-05T13:52:41.055Z","updated_at":"2024-07-02T16:36:06.416Z","phase":"Phase 3","brief_title":"Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.","source_id_and_acronym":"NCT05311943","lead_sponsor":"Shenzhen Second People's Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-07-29"}]